Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: mGluR2 modulators - Addex Pharmaceuticals/Ortho-McNeil

Drug Profile

Research programme: mGluR2 modulators - Addex Pharmaceuticals/Ortho-McNeil

Alternative Names: ADX 92639; JNJ-40068782

Latest Information Update: 07 Dec 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Addex Pharmaceuticals; Ortho-McNeil
  • Developer Addex Therapeutics; IRCCS Neuromed Mediterranean Neurological Institute; Ortho-McNeil
  • Class Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cognition disorders; Major depressive disorder; Stroke
  • Discontinued Anxiety disorders; Schizophrenia

Most Recent Events

  • 07 Dec 2016 Discontinued - Preclinical for Anxiety disorders in Europe (unspecified route)
  • 07 Dec 2016 Discontinued - Preclinical for Schizophrenia in Europe (unspecified route)
  • 07 Dec 2016 Preclinical trials in Cognition disorders in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top